DraftKings stock is down 30%, but 2025 profitability and growth prospects make it a compelling buy. Click here to read an ...

The disease under the proposal would receive the same reports that other tick-borne diseases such as Lyme disease currently ...

Boston Scientific has shown high revenue and EPS growth rates in recent years. See why I recommend a hold rating for BSX stock.

Completed dosing of first two cohorts in Phase 1/2a REWRITE Clinical Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD); Interim readout expected in the second half of 2025 -U.S. Food and ...

AlphaQuest LLC boosted its position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Free Report) by 16.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange ...